Skip to main content

Table 1 Demographic and clinicopathological characteristics

From: Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy

 

Training cohort (n = 287)

Internal validation cohort (n = 122)

External validation cohort (n = 65)

Age, median (IQR)

60 (54–67)

60 (51–66.3)

61 (52–69)

Gender (%)

 Male

127 (44.3)

60 (49.2)

27 (41.5)

 Female

160 (55.7)

62 (50.8)

38 (58.5)

Smoking history (%)

 Never

254 (88.5)

110 (90.2)

40 (61.5)

 Ever

33 (11.5)

12 (9.8)

25 (38.5)

Tumor location (%)

 Upper left

58 (20.2)

23 (18.9)

15 (23.1)

 Lower left

40 (13.9)

20 (16.4)

11 (16.9)

 Upper right

102 (35.5)

47 (38.5)

19 (29.2)

 Right middle

32 (11.1)

5 (4.1)

8 (12.3)

 Lower right

55 (19.2)

27 (22.1)

12 (18.5)

Pathological subtype (%)

 Lepidic

36 (12.5)

12 (9.8)

19 (29.2)

 Acinar/papillary

236 (82.2)

106 (86.9)

40 (61.5)

 Solid/micropapillary

15 (5.2)

4 (3.3)

6 (9.2)

Tumor size (cm)

 0–1

47 (16.4)

23 (18.9)

22 (33.8)

 1–2

146 (50.9)

53 (43.4)

17 (26.2)

 2–3

73 (25.3)

36 (29.5)

18 (27.7)

 3–4

21 (7.3)

10 (8.2)

8 (12.3)

TNM stage (%)

 IA1

45 (15.7)

20 (16.4)

22 (33.8)

 IA2

130 (45.3)

45 (36.9)

10 (15.4)

 IA3

62 (21.6)

31 (25.4)

7 (10.8)

 IB

50 (17.4)

26 (21.3)

26 (40.0)

Visceral pleural invasion (VPI, %)

 Absent

247 (86.1)

101 (82.8)

45 (69.2)

 Present

40 (13.9)

21 (17.2)

20 (30.8)

Lymphovascular invasion (LVI, %)

 Absent

278 (96.9)

119 (97.5)

64 (98.5)

 Present

9 (3.1)

3 (2.5)

1 (1.5)

Duration of follow-up, median (month)

92.3

92.4

26.6

Adjuvant chemotherapy (%)

32 (11.1)

11 (9.0)

NA

  1. IQR interquartile range, NA not available